Movano Inc. (MOVE) Q3 2024 10-Q Summary
Business Context and Reporting Period
This summary covers Movano Inc.'s (dba Movano Health) Form 10-Q for the quarterly period ended September 30, 2024. Movano is an early-stage technology company developing medical-grade health monitoring devices, primarily the "Evie Ring" for women's health. The company is classified as a smaller reporting company and an emerging growth company. All share and per-share data in this filing have been retroactively restated to reflect a 1-for-15 reverse stock split completed on October 29, 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $50,000 | $0 | $902,000 | $0 |
| Net Loss | $(7.2) million | $(9.0) million | $(19.1) million | $(23.3) million |
| Loss Per Share (Basic/Diluted) | $(1.06) | $(2.65) | $(3.33) | $(7.99) |
| Cash and Cash Equivalents | $11.3 million (as of Sept 30, 2024) | |||
| Accumulated Deficit | $(143.5) million (as of Sept 30, 2024) | |||
| Operating Cash Flow | N/A | $(18.0) million | $(20.9) million |
Material Changes vs. Prior Period
- Revenue Recognition: The company recorded $50,000 in revenue for Q3 2024 and $0.9 million for the nine months ended September 30, 2024, compared to zero in the prior year periods. This marks the beginning of commercial sales for the Evie Ring.
- Cost of Revenue: Costs rose to $0.8 million in Q3 2024 (from $0 in 2023), driven by direct product costs, labor, and a $0.5 million write-down of inventory designated as scrap materials.
- Expense Reduction: Operating expenses decreased by 18% in Q3 2024 compared to Q3 2023. Research and Development (R&D) expenses dropped 40% to $3.4 million, and Sales, General, and Administrative (SG&A) expenses fell 8% to $3.2 million, primarily due to reduced headcount and lower professional fees.
- Capital Raise: In April 2024, the company completed a private placement raising approximately $24.1 million in gross proceeds, significantly improving liquidity compared to the prior year.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. With $11.3 million in cash and a net loss of $19.1 million for the first nine months of 2024, the company expects to require additional financing to fund operations and R&D.
- Product Development: The company is pursuing FDA clearance for "EvieMED," a prescription version of the Evie Ring. A 510(k) submission for pulse oximetry was re-submitted in April 2024. They are also developing a proprietary System-on-a-Chip (SoC) for non-invasive glucose and cuffless blood pressure monitoring.
- Stock Listing: The company previously failed to meet Nasdaq's minimum bid price requirement. The 1-for-15 reverse stock split completed in October 2024 was intended to regain compliance, which was confirmed by Nasdaq in November 2024.
- Internal Controls: The company disclosed a material weakness in internal controls over financial reporting related to ineffective design and operation of financial close and reporting controls, which remains unremediated as of the filing date.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $11.3 million cash balance against the current burn rate (~$6.4 million per quarter) to assess the immediate need for further capital raises.
- Inventory Valuation: Review the $0.5 million inventory write-down in Q3 2024 and the remaining $2.0 million inventory balance for potential future obsolescence risks.
- Regulatory Timeline: Monitor the status of the FDA 510(k) re-submission for EvieMED, as commercial success depends heavily on regulatory clearance.
- Dilution Risk: Note the significant number of outstanding warrants (3.56 million shares) and options (0.76 million shares) that could dilute existing shareholders upon exercise.
- Internal Controls: Assess the progress of remediation efforts regarding the material weakness in financial reporting controls.